Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, of the Cleveland Clinic Taussig Cancer Institute in Ohio, joined Cancer Nursing Today at the 2024 American Society of Hematology Annual Meeting and Exposition to discuss her multiple myeloma research.
She presented multiple abstracts at the meeting, one of which focused on patient experiences with talquetamab, which is a GPRC5D-targeting bispecific antibody for myeloma.
“I think that it's an especially important role for nurses, advanced practitioners, and physicians alike to let patients know what to experience, give them suggestions for side effect management,” Dr. Faiman said.